Signal active
Organization
Contact Information
Overview
Aquinox Pharmaceuticals Inc., a pharmaceutical company, engages in discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer and inflammatory disease. It offers AQX-MN100, a drug used to treat cancer and inflammatory disease, as well as SH2-containing inositol 5'-phosphatase inhibition program for blood cell recovery. The company was founded in 2004 and is based in Vancouver, Canada.
About
Biotechnology, Health Care, Therapeutics
2004
11-50
Headquarters locations
North America
Social
N/A
Profile Resume
Aquinox Pharmaceuticals headquartered in North America, operates in the Biotechnology, Health Care, Therapeutics sector. The company focuses on Biotechnology and has secured $21.3B in funding across 96 round(s). With a team of 11-50 employees, Aquinox Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Aquinox Pharmaceuticals, raised $25.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
8
5
0
$221.4M
Details
3
Aquinox Pharmaceuticals has raised a total of $221.4M in funding over 3 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|---|---|---|---|
2007 | Early Stage Venture | 14.5M | ||
2013 | Late Stage Venture | 18.0M | ||
2010 | Early Stage Venture | 25.0M |
Investors
Aquinox Pharmaceuticals is funded by 30 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
Elaine Jones | - | FUNDING ROUND - Elaine Jones | 25.0M |
Pfizer Venture Investments | - | FUNDING ROUND - Pfizer Venture Investments | 25.0M |
Aquinox Pharmaceuticals | - | FUNDING ROUND - Aquinox Pharmaceuticals | 25.0M |
BC Advantage Funds | - | FUNDING ROUND - BC Advantage Funds | 25.0M |
Recent Activity
There is no recent news or activity for this profile.